RIVANNA®, developer of world-first imaging-based medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Accuro® 3S Needle Guide Kit consumables. This clearance marks a significant milestone in advancing the safety and effectiveness of ultrasound-guided needle placement.
https://mma.prnewswire.com/media/2847019/RIVANNA_Logo_Logo.jpg
The Accuro 3S Needle Guide Kit, designed for use with the Accuro 3S ultrasound imaging system and Dual-Array™ transducer, includes single-use, sterile components that support infection control and promote workflow efficiency. The sterile patient drape is equipped with stabilization bands that secure the transducer for hands-free support during needle approach, facilitating a streamlined, single-operator workflow. This configuration allows clinicians to maintain both hands on the needle for tactile feedback. The Dual-Array transducer supports midline placement through the probe's central aperture, while the integrated probe cover isolates the needle insertion site from contaminants to help maintain a controlled procedural field.
“The FDA clearance of the Accuro 3S Needle Guide Kit underscores our commitment to providing clinicians with intuitive, workflow-enhancing tools that enhance procedural accuracy and patient safety,” said Will Mauldin, PhD, Co-founder and CEO of RIVANNA. “The patient drape's stabilization bands, which secure the transducer for hands-free positioning, further distinguish our solution in the market by enabling single-operator efficiency and addressing a longstanding ergonomic challenge in real-time neuraxial needle placement.”
The Accuro 3S Needle Guide Kit reflects RIVANNA's commitment to advancing ultrasound-guided needle placement through innovative, user-friendly design, with safety and performance confirmed through comprehensive testing in accordance with FDA requirements.
About RIVANNA
RIVANNA is a commercial-stage medical device innovator and manufacturer based in Charlottesville, VA. RIVANNA develops and commercializes world-first, imaging-based medical technologies that elevate global standards of care. The company provides early- and late-stage comprehensive imaging solutions for point-of-care spinal needle interventionsand musculoskeletal diagnostics. Learn more: RIVANNA.
https://edge.prnewswire.com/c/img/favicon.png?sn=NE48820&sd=2025-12-16
View original content to download multimedia:https://www.prnewswire.com/news-releases/rivanna-announces-fda-clearance-of-accuro-3s-needle-guide-kit-302643819.html
SOURCE RIVANNA
https://rt.newswire.ca/rt.gif?NewsItemId=NE48820&Transmission_Id=202512161600PR_NEWS_USPR_____NE48820&DateId=20251216